Practice Guideline Summary: Sudden Unexpected Death in Epilepsy Incidence Rates and Risk Factors: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society by Harden, C et al.
180
This practice guideline was endorsed by the International Child 
Neurology Association on August 27, 2016. 
 
Epilepsy Currents, Vol. 17, No. 3 (May/June) 2017 pp. 180–187 
© American Epilepsy Society
American Epilepsy Society Guidelines 
Practice Guideline Summary: Sudden Unexpected Death in 
Epilepsy Incidence Rates and Risk Factors:  
Report of the Guideline Development, Dissemination, and 
Implementation Subcommittee of the American Academy 
of Neurology and the American Epilepsy Society
Cynthia Harden, MD1; Torbjörn Tomson, MD, PhD2; David Gloss, MD, MPH&TM3; Jeffrey Buchhalter, MD, PhD4; J. 
Helen Cross, MB, ChB, PhD5; Elizabeth Donner, MD6; Jacqueline A. French, MD7; Anthony Gil-Nagel, MD, PhD8; 
Dale C. Hesdorffer, PhD9; W. Henry Smithson, MB, ChB, MD10; Mark C. Spitz, MD11; Thaddeus S. Walczak, MD12; 
Josemir W. Sander, MD, PhD, FRCP13; Philippe Ryvlin, MD, PhD14
1Department of Neurology, Mount Sinai Health System, New York, NY
2Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
3Department of Neurology, CAMC Physicians, Charleston, WV
4Alberta Children’s Hospital, Departments of Pediatrics and Clinical Neurosciences, University of Calgary, Calgary, Canada
5Department of Clinical Neurosciences, University College London -  Institute of Child Health, and Great Ormond Street Hospital for Children 
NHS Foundation Trust, London, United Kingdom
6Division of Neurology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
7Department of Neurology, New York University Langone Comprehensive Epilepsy Center, New York, NY
8Department of Neurology, Hospital Ruber Internacional, Madrid, Spain
9Gertrude H. Sergievsky Center and Department of Epidemiology, Columbia University Medical Center, New York, NY
10Department of General Practice, University College Cork, Cork, Ireland
11Anschutz Outpatient Pavilion, University of Colorado Health, Aurora, CO
12Neurology Clinic, University of Minnesota, Minneapolis, MN
13University College London Institute of Neurology, London, United Kingdom, and Stichting Epilepsie Instellingen Nederland (SEIN), Heemstede, 
Netherlands
14Department of Clinical Neurosciences, CHUV, Lausanne, Switzerland
Address Correspondence to American Academy of Neurology: guidelines@aan.com
Approved by the Guideline Development, Dissemination, and Implementation Subcommittee on November 7, 2015; by the AAN Practice Com-
mittee on January 17, 2016; by the AES Guidelines Committee on November 11, 2016; by the AES Council on Clinical Activities on November 11, 
2016; by the AES Executive Committee on November 14, 2016; by the AES Board of Directors on November 30, 2016; and by the AAN Institute 
Board of Directors on January 11, 2017.
Objective: To determine the incidence rates of sudden unexpected death in epilepsy (SUDEP) in different epilepsy populations 
and address the question of whether risk factors for SUDEP have been identified. Methods: Systematic review of evidence; modi-
fied Grading Recommendations Assessment, Development and Evaluation process for developing conclusions; recommenda-
tions developed by consensus. Results: Findings for incidence rates based on 12 Class I studies include the following: SUDEP risk 
in children with epilepsy (aged 0 –17 years) is 0.22/1,000 patient-years (95% CI 0.16–0.31) (high confidence in evidence). SUDEP 
risk increases in adults to 1.2/1,000 patient-years (95% CI 0.64–2.32) (low confidence in evidence). The major risk factor for SUDEP 
is the occurrence of generalized tonic-clonic seizures (GTCS); the SUDEP risk increases in association with increasing frequency 
of GTCS occurrence (high confidence in evidence). Recommendations: Level B: Clinicians caring for young children with epilepsy 
should inform parents/guardians that in 1 year, SUDEP typically affects 1 in 4,500 children; therefore, 4,499 of 4,500 children will 
not be affected. Clinicians should inform adult patients with epilepsy that SUDEP typically affects 1 in 1,000 adults with epilepsy 
per year; therefore, annually 999 of 1,000 adults will not be affected. For persons with epilepsy who continue to experience GTCS, 
clinicians should continue to actively manage epilepsy therapies to reduce seizures and SUDEP risk while incorporating patient 
preferences and weighing the risks and benefits of any new approach. Clinicians should inform persons with epilepsy that seizure 
freedom, particularly freedom from GTCS, is strongly associated with decreased SUDEP risk.
ABBREVIATIONS
AAN: American Academy of Neurology
AED: antiepileptic drug
GTCS: generalized tonic-clonic seizures
SUDEP: sudden unexpected death in epilepsy
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INTRODUCTION
This document summarizes information provided in the 
complete guideline, available on the Neurology® Web site at 
Neurology.org. Appendix e-6, cited in the full guideline (data 
supplement), is available at Neurology.org.
Sudden unexpected death in epilepsy (SUDEP) is a poorly 
understood and catastrophic risk of epilepsy. The sensitive 
nature of discussions of this infrequent but important risk with 
patients and families has prompted the need for evidence-
based information about SUDEP. The goal of this practice 
guideline is to examine evidence for the SUDEP incidence rate 
in epilepsy populations and for prognostic factors for SUDEP 
occurrence. This in turn will inform an honest and balanced dis-
cussion when clinicians counsel people about SUDEP, and pro-
vide insight into areas where more clinical research is needed.
Two questions were asked:
1. What is the incidence rate of SUDEP in different epilepsy 
populations?
2. Are there specific risk factors for SUDEP?
DESCRIPTION OF THE ANALYTIC PROCESS
This practice guideline broadly follows the process delineated 
in the 2004 American Academy of Neurology (AAN) guideline 
development process manual,1 with the exception of the 
processes for formulating conclusions and recommendations, 
which follow the processes explained in the 2011 AAN guide-
line development process manual.2
In 2010, the AAN Guideline Development, Dissemination, 
and Implementation Subcommittee and the Guidelines Com-
mittee of the American Epilepsy Society convened a panel of 
experts to develop this practice guideline. The guideline panel 
engaged an independent medical librarian to search the MED-
LINE and Embase databases from earliest available article to 
November 2010. The panel then performed an identical search 
in April 2015 to include articles published since November 
2010. The keywords for both searches were SUDEP OR (sudden 
AND (unexplained OR unexpected) AND death) combined with 
the traditional medical subheadings (MeSh) for epilepsy ("Epi-
lepsy/abnormalities" OR "Epilepsy/classification" OR "Epilepsy/
complications" OR "Epilepsy/drug effects" OR "Epilepsy/drug 
therapy" OR "Epilepsy/epidemiology" OR "Epilepsy/ethnology" 
OR "Epilepsy/etiology" OR "Epilepsy/genetics" OR "Epilepsy/
mortality" OR "Epilepsy/physiopathology" OR "Epilepsy/preven-
tion and control" OR "Epilepsy/therapy") with limits of  “Hu-
mans”, plus “All Child: 0–18 years” or “All Adult: 19+ years”. Litera-
ture types were limited to “Clinical Trial, Randomized Controlled 
Trial, Comparative Study, Controlled Clinical Trial, Evaluation 
Studies, Journal Article, Multicenter Study, Research Support, 
N I H, Extramural, Research Support, N I H, Intramural, Research 
Support, Non US Gov't, Research Support, U S Gov't, Non P H S, 
Research Support, U S Gov't, P H S, Validation Studies.” Finally, 
the guideline panel specifically searched causes implicated in 
SUDEP (i.e., cardiac arrhythmias and preictal autonomic dys-
function), where the hypotheses were tested.
This search yielded 1,068 abstracts, all of which were 
reviewed for relevance by at least 2 panel members working 
independently of each other; 744 abstracts were not relevant 
to provide answers to the questions. Of the remaining 324 
abstracts, 2 panel members then obtained the full articles and 
reviewed them independently for inclusion. Reviewed articles 
were entered into a database application through an online 
questionnaire. Seventy articles had data for inclusion, and 254 
were excluded because they failed to address the questions, 
employ an adequate SUDEP definition, or use an appropri-
ate epilepsy comparison group in the prognostic studies. The 
available literature consisted of multiple Class I articles for 
incidence, and therefore articles rated Class II or lower were 
excluded because the Class II publications did not address 
populations not otherwise encompassed by the Class I articles. 
Several Class I and multiple Class II articles were available for 
prognostic questions.
Included articles were required to state that the SUDEP 
definition provided by Nashef 1997,3 Annegers 1997,4 and 
Leestma et al 19975 was used or to describe criteria in ac-
cordance with these definitions. These definitions share the 
following criteria, and the guideline panel included any article 
that incorporated these criteria in its SUDEP definition: (1) Pa-
tient had epilepsy by reasonable criteria without reference to 
the criteria used for epilepsy. (2) Deaths by drowning, trauma, 
or status epilepticus were excluded. (3) Death could have oc-
curred after a witnessed seizure. (4) Other competing causes of 
death were excluded.
The guideline panel used 2 of the AAN’s evidence-based 
schemes to rate articles: the screening criteria for the inci-
dence question and the prognostic criteria for the risk factor 
question.
Question 1: What is the incidence of SUDEP in different 
epilepsy populations?
Twelve Class I studies provided incidence rate data.6–17 Im-
precision in study findings resulted in high confidence in the 
evidence for SUDEP rates in childhood and low confidence in 
the evidence for SUDEP rates in adulthood and overall (see 
table 1). Because of imprecision in the incidence study results 
Table 1. Conclusions for SUDEP incidence
Population SUDEP/1000 pt-years (CI) Confidence
Overall 0.58 (0.31 to 1.08) Low
Childhood 0.22 (0.16 to 0.31) Moderate
“Adulthood” 1.2 (0.64 to 2.32) Low
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with a lack of overlap of 95% CIs between several comparable 
study populations, the guideline panel performed a random-
effects meta-analysis to provide summary measures of the 
absolute or relative risk of SUDEP. Additionally, to explore 
reasons for heterogeneity in the absolute risk of SUDEP 
reported, the panel conducted a meta-analysis of subgroups 
of studies including different groups of patients with epilepsy 
(e.g., children vs adults). These meta-analyses have significant 
unexplained heterogeneity, which may suggest the presence 
of other unknown or unexplored risk factors.
Rationale for recommendations 1 and 2
Our systematic review found that the SUDEP risk in children 
with epilepsy is 0.22/1,000 patient-years (95% CI 0.16–0.31). 
The SUDEP risk increases in adults to 1.2/1,000 patient-years 
(95% CI 0.64–2.32). There is considerable uncertainty regarding 
the estimates of the adult risk.
People with epilepsy and their families prefer to be 
informed of the individual’s risk for a catastrophic event 
such as SUDEP, even when the probability of the event is 
low.18 This preference is subject to cultural influences. After 
being informed of an adverse event, people commonly 
overestimate the risk of that adverse event’s happening to 
them.19 Such overestimation unduly increases the anxiety 
related to an adverse event. Overestimation can be lessened 
by presenting the risk as the probability of both having and 
not having the event,20 and by using numbers in addition to 
words19 and frequencies rather than percentages to convey 
the risk.21
 Incidence recommendation 1: SUDEP incidence in children
Clinicians caring for children with epilepsy should inform the 
children’s parents or guardians that (Level B for the following)
• There is a rare risk of SUDEP
• In 1 year, SUDEP typically affects 1 in 4,500 children with 
epilepsy; in other words, annually, 4,499 of 4,500 children 
will not be affected by SUDEP
Incidence recommendation 2: SUDEP incidence in adults
Clinicians should inform their adult persons with epilepsy that 
(Level B for the following)
• There is a small risk of SUDEP
In 1 year, SUDEP typically affects 1 in 1,000 adults with 
epilepsy; in other words, annually, 999 of 1,000 adults will not 
be affected by SUDEP
Question 2: Are there any risk factors for SUDEP?
Six Class I14,22–26 and 16 Class II articles6,7,17,23,27–38 provided evi-
dence for this question. Table 2 summarizes the results.
Rationale for recommendation 3
Our systematic review found that a major risk factor for 
SUDEP is the presence and frequency of generalized tonic-
clonic seizures (GTCS). For example, people with 3 or more 
GTCS per month have a 15-fold increased risk of SUDEP. This 
relative risk increase translates to an absolute risk of up to 
18 deaths per 1,000 patient-years for people with frequent 
GTCS.29
The large SUDEP risk increase from GTCS, coupled with epi-
lepsy monitoring unit evidence39 demonstrating that a GTCS 
was always the precipitating event of SUDEP, strongly suggests 
that GTCS are not just associated with SUDEP but, rather, are 
in the causal path to SUDEP. From this, it seems reasonable to 
infer that improved control of an individual’s GTCS will result 
in a reduced risk of SUDEP. Thus, a reduction in SUDEP risk 
is an additional benefit to the many benefits resulting from 
improved seizure control.
As with all benefits associated with improved seizure con-
trol, the potential benefit of SUDEP risk reduction needs to be 
balanced with the risks and burdens associated with antisei-
zure therapies.
Recommendation 3
For persons with epilepsy who continue to experience GTCS, 
clinicians should continue to actively manage epilepsy thera-
Table 2. Conclusions for SUDEP risk factors
Factor Odds ratio (Cl) Confidence level
Presence of GTCS vs lack of GTCS 10 (17–14) Moderate
Frequency of GTCS OR 5.07 (2.94–8.76) for 1–2 GTCS 
per y, and OR 15.46 (9.92–24.10) 
for >3 GTCS per y
High
Not being seizure free for 1–5 y 4.7 (1.4–16) Moderate
Not adding an AED when patients are medically refractory 6 (2–20) Moderate
Nocturnal supervision (risk reduction) 0.4 (0.2–0.8) Moderate
Use of nocturnal listening device (risk reduction) 0.1 (0–0.3) Moderate
Abbreviations: AED = antiepileptic drug; CI = confidence interval; GTCS = generalized tonic-clonic seizure; OR = odds ratio.
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pies to reduce seizure occurrences and the risk of SUDEP while 
incorporating patient preferences and weighing the risks and 
benefits of any new approach (Level B).
Rationale for recommendation 4
GTCS are clear risk factors for SUDEP, and nocturnal seizures 
may also increase risk. These findings, in conjunction with the 
observation that postictal respiratory depression is a major 
mechanism in SUDEP,39 suggest that unwitnessed noctur-
nal seizures and postictal respiratory depression can cause 
SUDEP.
Moreover, the presence in the bedroom of another individ-
ual at least 10 years of age and of normal intelligence is associ-
ated with a decreased SUDEP risk. These results imply that a 
bedroom observer could detect seizures, check on the patient, 
and provide sufficient stimulation to prevent respiratory arrest. 
This association does not indicate that these interventions 
directly mitigate the mechanism that causes SUDEP.
If it were in accordance with patient and family circum-
stances and values, nocturnal supervision could reduce SUDEP 
risk; however, providing nighttime observation might be 
overly burdensome and intrusive.
Recommendation 4
For persons with frequent GTCS and nocturnal seizures, clini-
cians may advise selected patients and families, if permitted by 
their individualized epilepsy and psychosocial circumstances, 
to use nocturnal supervision or other nocturnal precautions, 
such as the use of a remote listening device, to reduce SUDEP 
risk (Level C).
Rationale for recommendation 5
One of the most consistent findings of this review is that many 
factors that are indicators of uncontrolled epilepsy, includ-
ing having GTCS, having frequent GTCS, and the absence of 
seizure freedom, are strongly associated with SUDEP.
Usually, people with epilepsy and their families prefer 
to be informed of factors that are associated with an in-
creased risk of a catastrophic event such as SUDEP. Patients 
are especially interested in factors that might reduce their 
risk even when a causal link between the factor and a 
reduction in risk has not been established. Knowledge of 
these risk factors might suggest behaviors that could modi-
fy the risk factors (e.g., improved therapy adherence40), in-
crease the person’s sense of control, and reduce the anxiety 
that comes from awareness of the risk. Less severe seizure 
types, such as focal seizures or myoclonic seizures, are not 
proven to be associated with increased SUDEP risk, but 
individuals who have them often remain at risk for GTCS in 
the setting of therapy nonadherence. Therefore, therapy 
adherence to maintain freedom from GTCS is important 
even when an individual is not experiencing this severe 
seizure type.
Recommendation 5
Clinicians should inform their persons with epilepsy that sei-
zure freedom, particularly freedom from GTCS (which is more 
likely to occur with medication adherence), is strongly associ-
ated with a decreased risk of SUDEP (Level B).
Additional conclusions (no recommendations made)
The evidence is low that the following factors are associated 
with altering SUDEP risk:
• Nocturnal seizures (associated with increased risk)
• Any specific antiepileptic drug (AED) (none associated 
specifically with increased risk)
• Lamotrigine use is women (associated with increased risk)
• Never having been treated with an AED (associated with 
increased risk)
• Number of AEDs used overall (associated with increased 
risk)
• Heart rate variability (not associated with increased risk)
• Extratemporal epilepsy (associated with increased risk)
• Intellectual disability (associated with increased risk)
• Male gender (associated with increased risk)
• Anxiolytic drug use (associated with increased risk)
The evidence is very low or conflicting that the following 
factors are associated with altering SUDEP risk:
• Overall seizure frequency when evaluated by using all 
seizure types
• Medically refractory epilepsy vs not having well-con-
trolled seizures defined as no seizures for the past year
• Monotherapy vs polytherapy
• Carbamazepine, phenytoin, or sodium valproate levels 
that are above, below, or within the reference range
• Psychotropic drug use
• Mental health disorders, lung disorders, or alcohol use
• Lamotrigine use in people with highly refractory epilepsy
• Frequent changes in AEDs
• Therapeutic drug monitoring
• Undergoing a resective epilepsy surgical procedure (al-
though current research does not rule out the possibility 
of a beneficial effect or, further, the potential effect of epi-
lepsy surgery on reducing GTCS frequency and epilepsy 
severity on reducing SUDEP risk)
• Engel outcome of epilepsy surgery (although current 
research does not rule out the possibility of a beneficial 
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effect and, further, the potential effect of epilepsy surgery 
on reducing GTCS frequency and epilepsy severity on 
reducing SUDEP risk)
• Vagus nerve stimulator use for more than 2 years (how-
ever, current research does not rule out the possibility of 
a beneficial effect and, further, the potential effect of epi-
lepsy surgery on reducing GTCS frequency and epilepsy 
severity on reducing the risk of SUDEP)
• Epilepsy etiology, whether idiopathic or localization 
related
• Structural lesion on MRI
• Duration of epilepsy
• Age at epilepsy onset
• Postictal EEG suppression
SUGGESTIONS FOR FUTURE RESEARCH
1. Systematic methods should be developed to identify and 
report the incidence of SUDEP in different epilepsy popula-
tions in order to obtain a better understanding of the 
incidence and causes of this devastating condition.
2. Educational efforts are needed to improve the forensic 
knowledge of SUDEP among professionals such as medical 
examiners, coroners, and pathologists in order to help de-
termine, and document on death certificates, the etiology 
in individuals, and in order to improve overall knowledge 
of this condition.
3. Research to identify preventable risk factors should be 
supported and encouraged so that future clinical trials will 
be conducted to reduce SUDEP occurrence. Of particular 
importance is to better understand (a) the relationship 
between the nature, severity, and duration of epilepsy and 
the occurrence of SUDEP, and (b) whether current treat-
ments affect the risk of developing SUDEP.
4. Because of (a) risks identified with frequent GTCS, (b) the 
fact that one study shows more SUDEP events occur in 
people in placebo arms of trials, and (c) increased SUDEP 
risk, serious consideration should be given to avoid assign-
ing people with frequent GTCS to placebo for long periods.
DISCLAIMER
Clinical practice guidelines, practice advisories, systematic 
reviews and other guidance published by the American Acad-
emy of Neurology and its affiliates are assessments of current 
scientific and clinical information provided as an educational 
service. The information: 1) should not be considered inclusive 
of all proper treatments, methods of care, or as a statement of 
the standard of care; 2) is not continually updated and may not 
reflect the most recent evidence (new evidence may emerge 
between the time information is developed and when it is 
published or read); 3) addresses only the question(s) specifically 
identified; 4) does not mandate any particular course of medical 
care; and 5) is not intended to substitute for the independent 
professional judgment of the treating provider, as the informa-
tion does not account for individual variation among patients. 
In all cases, the selected course of action should be considered 
by the treating provider in the context of treating the individual 
patient. Use of the information is voluntary. AAN provides 
this information on an “as is” basis, and makes no warranty, 
expressed or implied, regarding the information. AAN specifi-
cally disclaims any warranties of merchantability or fitness for a 
particular use or purpose. AAN assumes no responsibility for any 
injury or damage to persons or property arising out of or related 
to any use of this information or for any errors or omissions.
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